Cure research
- Gene editing/therapy correction of causal variants (PKD1/PKD2)
- RNA-targeted correction/silencing strategies
- Cell/organ regenerative replacement concepts
- Multi-pathway disease interception (beyond single-target)
ADPKD cure research, clinical trials, and new evidence
Track real movement without overselling early signals.
Last reviewed: June 1, 2026
Featured trials
- NCT07282821, Phase 2, NOT_YET_RECRUITING
- NCT07454174, Pilot (NA), RECRUITING
- NCT07280585, Phase 3, RECRUITING
- NCT04939935, Phase 3, RECRUITING
- NCT06800651, Phase 2, RECRUITING
Useful jumps
Latest meaningful movement
- Key new evidence this run , GLPG2737 / CFTR inhibition failed in the phase 2a MANGROVE study: it did not reduce htTKV growth or slow eGFR decline versus placebo in rapidly progressive ADPKD (PMID42201338).
- Four-track review outcome
- What strengthened , The negative CFTR result cleaned up a weak hypothesis.